ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 22 of 43
Up
УЖМБС 2017, 2(2): 128–132
https://doi.org/10.26693/jmbs02.02.128
Clinical Medicine

Allergic Rhinitis and Quality of Life in Patients with Bronchial Asthma

Cherniakova A. E., Ospanova T. S., Karmazina I. S.
Abstract

Bronchial asthma (BA) and allergic rhinitis (AR) are the most widespread allergic diseases. Nowadays, allergic diseases are concerned as a global challenge of medical care due to their sustained expansion: 30-40 percent of Earth population suffers from one or more allergic diseases. Number of patients, who suffer from allergy, has been doubling every decade for last 30 years. According to the World Allergy Organization’s (WAO) data, 300 millions of people suffer from BA, and 250 thousands of them die every year. BA and AR significantly impair the quality of life (QL) of patients; these diseases impact social and economic well-being of society. AR is the risk factor of BA development; combination of BA and AR is found out in 15-38 per cent of cases (I.L. Brozek et al., 2010; J. Bousquest et al., 2012). The aim is to assess allergic rhinitis influence on the quality of life in patients with bronchial asthma. Materials and methods It was investigated 30 patients with BA, who took medical care in Kharkiv regional hospital. BA of the 2nd degree (mild persistent) has been diagnosed in 10 patients, BA of the 3rd degree (moderate persistent) – in 12 patients, and BA of the 4th degree (severe) – in 8 patients. Uncontrolled clinical course of BA has been ascertained in 14 patients and partially controlled – in 16 persons. For the research of patients QL general international questionnaire MOS SF-36 has been used. Results of questioning have been calculated with the help of special computer program and represented in points of scale from 0 to 100 (www. sf-36.org/demos/SF-36/html). Statistical processing of data has been used for figures assessment (Excel for Windows 10, STATISTICA 7.0). Results and discussion For the analysis of AR influence on the QL of patients with BA patients were separated into two groups: 1st group included 9 patients with both BA and AR, 2nd group contained 21 patients with BA but without symptoms of AR. It has been found out that parameters of physical health (PCS) have not been significantly different in both groups. Nevertheless, summary parameters of mental health (MCS) such as viability (VT), social functioning (SF), role of emotions (RE) and mental health (MH) have been lower in patients of the 1st group than in the 2nd one. It was defined two sub-phenotypes of patients with BA. Thus, BA sub-phenotype with low parameters of mental health (MCS 34-37 points) has been established in young patients (20-39 y. o.), mainly men with either BA or AR. Meanwhile, BA sub-phenotype with relatively high QL parameters (MCS 39-45 points) has been demonstrated in women, and in patients with normal arterial pressure and without symptoms of AR. Conclusions. The research of QL in patients with BA and AR with the help of general international questionnaire MOS SF-36 has revealed that AR did not affect the physical health of patients with BA. AR has impacted parameters of mental health on patients with BA. To improve treatment and follow-up care of patients with BA and AR two sub-phenotypes, which are characterized by high and low parameters of mental health, have been offered to identify. Patients with BA, who have low parameters of mental health, must follow recommendations strictly of the Protocols for AR and arterial hypertension treatment and the program of their rehabilitation should involve psychotherapeutic care. Following researches are necessary to identify BA and AR biomarkers for patient phenotyping and personification of approaches for allergic diseases diagnostics and treatment.

Keywords: bronchial asthma, allergic rhinitis, quality of life, phenotype

Full text: PDF (Rus) 198K

References
  1. Belaya kniga WAO po allergii 2011-2012. Rezyume. Pod red. akad. AN Gruzii RI Sepiashvili, prof GF Slavyanskoy. M: Meditsina-Zdorov'ye; 2011. 12 s.
  2. Bezsheyko VG. Montelukast v terapii allergicheskogo rinita i nazal'nykh polipov: mekhanizm deystviya, klinicheskaya effektivnost'. Ukr med chasopis. 2013; 3 (95): 101-5.
  3. Drannik GN. Klinicheskaya immunologiya i allergologiya: posobiye dlya studentov, vrachey-internov, immunologov, allergologov, vrachey lechebnogo profilya vsekh spetsial'nostey. 4-ye izd, dop. K; 2010. 552 s.
  4. Kaydashev IP. MACVIA-ARIA – signal'na merezha kontrolyu alergíchnogo rinítu (MASK-rinít): vprovadzhennya rekomendatsíy novogo pokolínnya. Сlín ímunologíya. Alergologíya. Infektologíya. 2016; 6 (95): 5-14.
  5. Pukhlik BM, Pukhlik SM, Korshunov IV, i dr. Sovremennyye vzglyady na problemu lecheniya allergicheskogo rinita. Ukr pul'monol zhurnal. 2004; 2: 18-21.
  6. Feshchenko YuI, Yashina LA, Polyanskaya MA, i dr. Rezul'taty issledovaniya primeneniya modifikatorov leykotriyenov u bol'nykh bronkhial'noy astmoy. Astma i allergiya. 2011; 4: 5-12.
  7. Akdis M, Blaser K, Akdis CA. T-regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy and Clin Immun. 2005; 116: 961-9. https://doi.org/http://dx.doi.org/10.1016/j.jaci.2005.09.004
  8. Aydemir O, Sacar A, Kirmaz C, et al. Quality of life in asthma and allergic rhinitis: a hospital-based comparative study. Turkish Respiratory Journ. 2006; 7 (3): 101-4.
  9. Bellido-Casado J, Martin-Escudero J, Duenas-Laita A, Mena-Martín FJ, Arzúa-Mouronte D, Simal-Blanco F. The SF-36 questionnaire as measurement of health-related quality of life: assessing short- and medium-term effects of exposure to tobacco versus the known long-term effects. European J Intern Med. 2004; 15 (8): 511-7. https://doi.org/10.1016/j.ejim.2004.06.015
  10. Berger W, Hampel F, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006; 97 (3): 375-81. https://doi.org/10.1016/S1081-1206(10)60804-6
  11. Bousquet J, Schunemann HJ, Samolinsk B, et al. Allergic rhinitis and its impact on asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012; 130 (5): 1049-62. https://doi.org/10.1016/j.jaci.2012.07.053
  12. Bousquet J, Duchateau J, Pignat JC, Fayol C, Marquis P, Mariz S, Ware JE, Valentin B, Burtin B. Improvement of quality of life by treatment with cetirizine in patient with perennial allergic rhinitis as determined by a French version of the SF–36 questionnaire. J Allergy Clin Immunol. 1996; 98 (2): 309-16. https://www.ncbi.nlm.nih.gov/pubmed/8757208
  13. Brozek IL, Bousqet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its impact on asthma (ARIA). Guidelines revision. 2010; 9/8: 153 p.
  14. Lakhani N, North M, Ellis AK. Clinical manifestations of allergic rhinitis. J of Allergy and Therapy. 2012; 5: 5:007. https://doi.org/10.4172/2155-6121.55.007.
  15. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Care Med. 2000; 162 (4/1): 1391-6. https://doi.org/10.1164/ajrccm.162.4.9912033
  16. Seidman MD, Gurgel RK, Lin SG, Schwartz SR, Baroody FM, Bonner JR, Dawson DE, Dykewicz MS, Hackell JM, Han JK, Ishman SL, Krouse HJ, Malekzadeh S, Mims JW, Omole FS, Reddy WD, Wallace DV, Walsh SA, Warren BE, Wilson MN, Nnacheta LC. Clinical practice guideline: Allergic rhinitis. Otolaringol Head Neck Surg. 2015; 152 (1 Suppl): 1-43. https://doi.org/10.1177/0194599814561600
  17. Selye H. Allergy and the Genera Adaptation Syndrome. Int Archs Allergy appl Immun. 1952; 111 (4): 267-78. https://doi.org/10.1159/000227975
  18. Sritipsukho P, Satdhabudha A, Nanthapisal S. Effect of allergic rhinitis and asthma on the quality of life in young Thai adolescents. Asian Pac J Allergy Immunol. 2015; 33 (3): 222-6. https://doi.org/10.12932/AP0548.33.3.2015
  19. Thompson AK, Juniper E, Metzer EQ. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 2000; 85 (5): 338-43. https://doi.org/10.1016/S1081-1206(10)62543-4
  20. Ware JE, Sherbourne CA. The MOS-36 – item short form health survey (SF-36): conceptual framework and item selection. Med Care. 1992; 30: 473-83. https://www.ncbi.nlm.nih.gov/pubmed/1593914